Skip to main content
. 2019 Mar 19;24(8):1103–1110. doi: 10.1634/theoncologist.2018-0380

Table 6. General dose modification guidelines for lorlatinib‐related adverse reactions by CTCAE gradea .

image

a

Based on CTCAE (v4.03).

Permanent discontinuation is recommended if patient is unable to tolerate lorlatinib 50 mg taken orally once daily.

Abbreviation: CTCAE, Common Terminology Criteria for Adverse Events.